Literature DB >> 10327055

Wild-type p53 protein shows calcium-dependent binding to F-actin.

S Metcalfe1, A Weeds, A L Okorokov, J Milner, M Cockman, B Pope.   

Abstract

Nuclear localization of p53 is required for p53 to detect and respond to DNA strand abnormalities and breaks following DNA damage. This leads to activation of the tumour suppressive functions of p53 resulting in either cell cycle arrest and DNA repair; or apoptosis. Critical functional changes in DNA which require strand breaks, including gene rearrangement, may transiently mimic DNA damage: here it is important not to trigger a p53 response. The fine control of p53 in these different circumstances is unknown but may include transient sequestering of p53 in the cytoplasm. Reversible nuclear-cytoplasmic shuttling is an intrinsic property of p53 (Middeler et al., 1997) associated with cell cycle-related changes in p53's subcellular distribution. Takahashi and Suzuki (1994) described p53 inactivation by shuttling to the cytoplasm and Katsumoto et al. (1995) found wild-type p53 to be closely associated with cytoplasmic actin filaments during DNA synthesis. Here we show that, in the presence of free calcium ions, p53 binds directly to F-actin with a dissocation constant of about 10 microM. Thus, part of the regulatory machinery in normal cell cycling may involve p53-actin interactions regulated by calcium fluxes and the dynamic turnover of F-actin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10327055     DOI: 10.1038/sj.onc.1202559

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Regulation of Cdc42-mediated morphological effects: a novel function for p53.

Authors:  Gilles Gadéa; Laure Lapasset; Cécile Gauthier-Rouvière; Pierre Roux
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 2.  The nucleoskeleton as a genome-associated dynamic 'network of networks'.

Authors:  Dan N Simon; Katherine L Wilson
Journal:  Nat Rev Mol Cell Biol       Date:  2011-10-05       Impact factor: 94.444

3.  Tunneling-nanotube development in astrocytes depends on p53 activation.

Authors:  Y Wang; J Cui; X Sun; Y Zhang
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

4.  Nuclear α-catenin mediates the DNA damage response via β-catenin and nuclear actin.

Authors:  Leonid A Serebryannyy; Alex Yemelyanov; Cara J Gottardi; Primal de Lanerolle
Journal:  J Cell Sci       Date:  2017-03-27       Impact factor: 5.285

5.  LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization.

Authors:  Stacy Visser-Grieve; Zhonghua Zhou; Yi-Min She; He Huang; Terry D Cyr; Tian Xu; Xiaolong Yang
Journal:  Cell Res       Date:  2011-08-02       Impact factor: 25.617

Review 6.  There is more than one way to model an elephant. Experiment-driven modeling of the actin cytoskeleton.

Authors:  Jonathon A Ditlev; Bruce J Mayer; Leslie M Loew
Journal:  Biophys J       Date:  2013-02-05       Impact factor: 4.033

7.  Mitochondrial dysfunction impairs tumor suppressor p53 expression/function.

Authors:  Shannon Compton; Chul Kim; Nicholas B Griner; Prasanth Potluri; Immo E Scheffler; Sabyasachi Sen; D Joseph Jerry; Sallie Schneider; Nagendra Yadava
Journal:  J Biol Chem       Date:  2011-04-18       Impact factor: 5.157

Review 8.  β-Actin: An Emerging Biomarker in Ischemic Stroke.

Authors:  Jiaqian Li; Fangyu Dai; Xuelian Kou; Bin Wu; Jie Xu; Songbin He
Journal:  Cell Mol Neurobiol       Date:  2022-05-13       Impact factor: 5.046

9.  UFFizi: a generic platform for ranking informative features.

Authors:  Assaf Gottlieb; Roy Varshavsky; Michal Linial; David Horn
Journal:  BMC Bioinformatics       Date:  2010-06-03       Impact factor: 3.169

10.  Relationship between serum calcium and CA 19-9 levels in colorectal cancer.

Authors:  Peter Fuszek; Peter Lakatos; Adam Tabak; Janos Papp; Zsolt Nagy; Istvan Takacs; Henrik Csaba Horvath; Peter Laszlo Lakatos; Gabor Speer
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.